Aurinia Pharmaceuticals (AUPH) Revenue & Revenue Breakdown


OverviewForecastOwnershipFinancialsChartTranscripts

Aurinia Pharmaceuticals Revenue Highlights


Latest Revenue (Y)

$158.53M

Latest Revenue (Q)

$57.19M

Main Segment (Y)

Product

Main Geography (Y)

UNITED STATES

Aurinia Pharmaceuticals Revenue by Period


Aurinia Pharmaceuticals Revenue by Year

DateRevenueChange
2023-12-31$158.53M18.28%
2022-12-31$134.03M193.89%
2021-12-31$45.60M-9.00%
2020-12-31$50.12M15660.38%
2019-12-31$318.00K-31.32%
2018-12-31$463.00K10.24%
2017-12-31$420.00K142.77%
2016-12-31$173.00K-26.38%
2015-12-31$235.00K-15.47%
2014-12-31$278.00K-70.69%
2013-12-31$948.56K-84.60%
2012-12-31$6.16M563.90%
2011-12-31$927.52K-72.88%
2010-12-31$3.42M-15.59%
2009-12-31$4.05M4.52%
2008-12-31$3.88M66.05%
2007-12-31$2.33M-33.72%
2006-12-31$3.52M199.06%
2005-12-31$1.18M-7.51%
2004-12-31$1.27M-83.38%
2003-12-31$7.66M-35.71%
2002-12-31$11.92M124.97%
2001-12-31$5.30M486.77%
2000-11-30$902.77K-33.53%
1999-11-30$1.36M73.85%
1998-11-30$781.25K-

Aurinia Pharmaceuticals generated $158.53M in revenue during NA 2023, up 18.28% compared to the previous quarter, and up 34240.39% compared to the same period a year ago.

Aurinia Pharmaceuticals Revenue by Quarter

DateRevenueChange
2024-06-30$57.19M13.70%
2024-03-31$50.30M11.55%
2023-12-31$45.09M-17.28%
2023-09-30$54.52M31.38%
2023-06-30$41.49M20.59%
2023-03-31$34.41M21.01%
2022-12-31$28.43M-49.02%
2022-09-30$55.78M97.86%
2022-06-30$28.19M30.36%
2022-03-31$21.63M-7.60%
2021-12-31$23.40M59.57%
2021-09-30$14.67M121.56%
2021-06-30$6.62M624.29%
2021-03-31$914.00K-98.17%
2020-12-31$50.03M172417.24%
2020-09-30$29.00K-
2020-06-30$29.00K-3.33%
2020-03-31$30.00K3.45%
2019-12-31$29.00K-87.39%
2019-09-30$230.00K693.10%
2019-06-30$29.00K-3.33%
2019-03-31$30.00K3.45%
2018-12-31$29.00K-92.27%
2018-09-30$375.00K1193.10%
2018-06-30$29.00K-3.33%
2018-03-31$30.00K-3.23%
2017-12-31$31.00K6.90%
2017-09-30$29.00K-91.19%
2017-06-30$329.00K961.29%
2017-03-31$31.00K3.33%
2016-12-31$30.00K-3.23%
2016-09-30$31.00K-43.64%
2016-06-30$55.00K-3.51%
2016-03-31$57.00K-
2015-12-31$57.00K-
2015-09-30$57.00K-3.39%
2015-06-30$59.00K-4.84%
2015-03-31$62.00K-8.82%
2014-12-31$68.00K-5.56%
2014-09-30$72.00K1.41%
2014-06-30$71.00K5.97%
2014-03-31$67.00K-90.33%
2013-12-31$692.64K721.28%
2013-09-30$84.34K2.00%
2013-06-30$82.69K-5.47%
2013-03-31$87.47K1.47%
2012-12-31$86.21K-1.34%
2012-09-30$87.38K-1.26%
2012-06-30$88.49K-98.48%
2012-03-31$5.81M4745.76%
2011-12-31$119.97K-77.57%
2011-09-30$534.84K250.00%
2011-06-30$152.81K10.83%
2011-03-31$137.87K-53.70%
2010-12-31$297.75K12.95%
2010-09-30$263.62K-81.35%
2010-06-30$1.41M-2.37%
2010-03-31$1.45M-12.58%
2009-12-31$1.66M72.55%
2009-09-30$959.87K55.20%
2009-06-30$618.46K-4.42%
2009-03-31$647.03K592.40%
2008-12-31$93.45K-96.54%
2008-09-30$2.70M386.86%
2008-06-30$555.12K-1.32%
2008-03-31$562.52K-8.72%
2007-12-31$616.27K-

Aurinia Pharmaceuticals generated $57.19M in revenue during Q2 2024, up 13.70% compared to the previous quarter, and up 166.21% compared to the same period a year ago.

Aurinia Pharmaceuticals Revenue Breakdown


Aurinia Pharmaceuticals Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23Dec 22Dec 21Dec 20
Product$158.53M$103.47M$45.49M-
License, Collaboration and Royalty Revenue$16.98M---
License-$30.56M$117.00K$50.12M

Aurinia Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (90.33%), and License, Collaboration and Royalty Revenue (9.67%).

Quarterly Revenue by Product

Product/ServiceSep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21
Product$55.50M$55.03M$48.07M$42.31M$40.78M$41.10M$34.34M$28.33M$25.50M$28.15M$21.49M$23.38M$14.64M$6.59M$30.00K
License, Royalty and Collaboration Revenue$12.27M$2.16M$2.23M$13.73M$394.00K$72.00K---------
License-------$109.00K$30.28M$43.00K$133.00K$29.00K$29.00K$29.00K$884.00K

Aurinia Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Product (81.90%), and License, Royalty and Collaboration Revenue (18.10%).

Aurinia Pharmaceuticals Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 23Dec 22Dec 21Dec 20Dec 19
UNITED STATES$157.96M$102.46M$45.49M-$200.00K
JAPAN$17.55M$31.48M-$50.00M-
Other Country-$89.00K$117.00K--
CHINA---$118.00K$118.00K

Aurinia Pharmaceuticals's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (90.00%), and JAPAN (10.00%).

Aurinia Pharmaceuticals Peer Comparison by Revenue


TickerCompanyLast Year RevenueLast Quarter Revenue
EXELExelixis$1.83B$478.06M
SRPTSarepta Therapeutics$1.24B$362.93M
PTCTPTC Therapeutics$937.82M$135.42M
AXSMAxsome Therapeutics$270.60M$87.17M
TGTXTG Therapeutics$233.66M$83.88M
AUPHAurinia Pharmaceuticals$158.53M$57.19M
MCRBSeres Therapeutics$126.33M-
BTAIBioXcel Therapeutics$1.38M$1.10M
VKTXViking Therapeutics--
MDGLMadrigal Pharmaceuticals-$62.17M
TERNTerns Pharmaceuticals--
AKROAkero Therapeutics--
HEPAHepion Pharmaceuticals--

AUPH Revenue FAQ


What is Aurinia Pharmaceuticals’s yearly revenue?

Aurinia Pharmaceuticals's yearly revenue for 2023 was $158.53M, representing an increase of 18.28% compared to 2022. The company's yearly revenue for 2022 was $134.03M, representing an increase of 193.89% compared to 2021. AUPH's yearly revenue for 2021 was $45.6M, representing a decrease of -9.00% compared to 2020.

What is Aurinia Pharmaceuticals’s quarterly revenue?

Aurinia Pharmaceuticals's quarterly revenue for Q2 2024 was $57.19M, a 13.70% increase from the previous quarter (Q1 2024), and a 37.83% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $50.3M, a 11.55% increase from the previous quarter (Q4 2023), and a 46.19% increase year-over-year (Q1 2023). AUPH's quarterly revenue for Q4 2023 was $45.1M, a -17.28% decrease from the previous quarter (Q3 2023), and a 58.59% increase year-over-year (Q4 2022).

What is Aurinia Pharmaceuticals’s revenue growth rate?

Aurinia Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was 247.62%, and for the last 5 years (2019-2023) was 49753.14%.

What are Aurinia Pharmaceuticals’s revenue streams?

Aurinia Pharmaceuticals's revenue streams in c 23 are Product, and License, Collaboration and Royalty Revenue. Product generated $158.53M in revenue, accounting 90.33% of the company's total revenue, up 53.22% year-over-year. License, Collaboration and Royalty Revenue generated $16.98M in revenue, accounting 9.67% of the company's total revenue

What is Aurinia Pharmaceuticals’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of Aurinia Pharmaceuticals was Product. This segment made a revenue of $158.53M, representing 90.33% of the company's total revenue.